Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2014

01-03-2014 | Research Article

HIV-1 viral protein R downregulates Ebp1 and stabilizes p53 in glioblastoma U87MG cells

Authors: S. Zhang, B. Zhang, X. Xu, L. Wang, X. Feng, Q. Wang, H. Huang, J. Wu, P. Li, J. Wang

Published in: Clinical and Translational Oncology | Issue 3/2014

Login to get access

Abstract

Purpose

HIV-1 viral protein R (Vpr) inhibits cell growth and induces apoptosis in a wide range of cancers. However, the mechanism by which Vpr induces cell cycle arrest and apoptosis in GBM cell lines is unclear. The present work was taken to detect the proteins interacted with Vpr in U87MG cells.

Methods

We analyzed the differential expression of proteins between glioblastoma cell U87MG treated with Ad-Vpr and untreated by 2-DE. We used antibody array analysis to analyze the common molecules in the apoptosis of U87MG induced by Vpr.

Results

We analyzed the differential expression of proteins between U87MG cell treated with Ad-Vpr and untreated, and found that proteins related to DNA damage repair or different apoptosis pathways were involved in the G2 arrest and apoptosis mediated by Vpr. In addition, proliferation-associated protein 2G4 (PA2G4), also known as Ebp1, was down-regulated and p53 was up-regulated in U87MG cells treated with Ad-Vpr.

Conclusions

Our data suggest that Vpr may inhibit Ebp1 to stabilize p53, which in turn leads to G2 arrest and apoptosis in U87MG cells.
Literature
1.
Andersen JL, Le Rouzic E, Planelles V. HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. Exp Mol Pathol. 2008;85:2–10.
2.
Langevin C, Maidou-Peindara P, Aas PA, Jacquot G, Otterlei M, Slupphaug G, et al. Human immunodeficiency virus type 1 Vpr modulates cellular expression of UNG2 via a negative transcriptional effect. J Virol. 2009;83:10256–63.PubMedCentralPubMedCrossRef
3.
Withers-Ward ES, Mueller TD, Chen IS, Feigon J. Biochemical and structural analysis of the interaction between the UBA(2) domain of the DNA repair protein HHR23A and HIV-1 Vpr. Biochemistry-Us. 2000;39:14103–12.
4.
Planelles V, Benichou S. Vpr and its interactions with cellular proteins. Curr Top Microbiol Immunol. 2009;339:177–200.
5.
Zhang B, Feng X, Wang J, Xu X, Lin N, Liu H. Combined antitumor effect of Ad-bFGF-siRNA and Ad-Vpr on the growth of xenograft glioma in nude mouse model. Pathol Oncol Res. 2011;17:237–42.PubMedCrossRef
6.
Nakai-Murakami C, Minemoto Y, Ishizaka Y. Vpr-induced DNA double-strand breaks: molecular mechanism and biological relevance. Curr HIV Res. 2009;7:109–13.PubMedCrossRef
7.
Nakai-Murakami C, Shimura M, Kinomoto M, Takizawa Y, Tokunaga K, Taguchi T, et al. HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination. Oncogene. 2007;26:477–86.PubMedCrossRef
8.
Tachiwana H, Shimura M, Nakai-Murakami C, Tokunaga K, Takizawa Y, Sata T, et al. HIV-1 Vpr induces DNA double-strand breaks. Cancer Res. 2006;66:627–31.PubMedCrossRef
9.
Lai M, Zimmerman ES, Planelles V, Chen J. Activation of the ATR pathway by human immunodeficiency virus type 1 Vpr involves its direct binding to chromatin in vivo. J Virol. 2005;79:15443–51.PubMedCentralPubMedCrossRef
10.
Harrison JC, Haber JE. Surviving the breakup: the DNA damage checkpoint. Annu Rev Genet. 2006;40:209–35.
11.
Capanni C, Cenni V, Haraguchi T, Squarzoni S, Schuchner S, Ogris E, et al. Lamin A precursor induces barrier-to-autointegration factor nuclear localization. Cell Cycle. 2010;9:2600–10.
12.
Peter A, Reimer S. Evolution of the lamin protein family: what introns can tell. Nucleus. 2012;3:44–59.PubMedCrossRef
13.
Watanabe N, Yamaguchi T, Akimoto Y, Rattner JB, Hirano H, Nakauchi H. Induction of M-phase arrest and apoptosis after HIV-1 Vpr expression through uncoupling of nuclear and centrosomal cycle in HeLa cells. Exp Cell Res. 2000;258:261–9.
14.
Moon HS, Yang JS. Role of HIV Vpr as a regulator of apoptosis and an effector on bystander cells. Mol Cells. 2006;21:7–20.
15.
16.
Ma B, Zhang H, Wang J, Zhang B, Xu X, Cheng B. HIV-1 viral protein R (Vpr) induction of apoptosis and cell cycle arrest in multidrug-resistant colorectal cancer cells. Oncol Rep. 2012;28:358–64.PubMed
17.
Muthumani K, Hwang DS, Desai BM, Zhang D, Dayes N, Green DR, et al. HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem. 2002;277:37820–31.
18.
Snyder A, Alsauskas ZC, Leventhal JS, Rosenstiel PE, Gong P, Chan JJ, et al. HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells. Aids. 2010;24:1107–19.
19.
20.
Yoo JY, Wang XW, Rishi AK, Lessor T, Xia XM, Gustafson TA, et al. Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. Br J Cancer. 2000;82:683–90.
21.
Liu Z, Ahn JY, Liu X, Ye K. Ebp1 isoforms distinctively regulate cell survival and differentiation. Proc Natl Acad Sci USA. 2006;103:10917–22.PubMedCrossRef
22.
Kim CK, Nguyen TL, Joo KM, Nam DH, Park J, Lee KH, et al. Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. Cancer Res. 2010;70:9730–41.
23.
Liu Z, Oh SM, Okada M, Liu X, Cheng D, Peng J, et al. Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor. Mol Biol Cell. 2009;20:757–68.
24.
Amini S, Saunders M, Kelley K, Khalili K, Sawaya BE. Interplay between HIV-1 Vpr and Sp1 modulates p21(WAF1) gene expression in human astrocytes. J Biol Chem. 2004;279:46046–56.PubMedCrossRef
25.
Chowdhury IH, Wang XF, Landau NR, Robb ML, Polonis VR, Birx DL, et al. HIV-1 Vpr activates cell cycle inhibitor p21/Waf1/Cip1: a potential mechanism of G2/M cell cycle arrest. Virology. 2003;305:371–7.PubMedCrossRef
26.
Muthumani K, Zhang D, Hwang DS, Kudchodkar S, Dayes NS, Desai BM, et al. Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines. Oncogene. 2002;21:4613–25.PubMedCrossRef
27.
Kim CK, Lee SB, Nguyen TL, Lee KH, Um SH, Kim J, et al. Long isoform of ErbB3 binding protein, p48, mediates protein kinase B/Akt-dependent HDM2 stabilization and nuclear localization. Exp Cell Res. 2012;318:136–43.PubMedCrossRef
Metadata
Title
HIV-1 viral protein R downregulates Ebp1 and stabilizes p53 in glioblastoma U87MG cells
Authors
S. Zhang
B. Zhang
X. Xu
L. Wang
X. Feng
Q. Wang
H. Huang
J. Wu
P. Li
J. Wang
Publication date
01-03-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1072-7

Other articles of this Issue 3/2014

Clinical and Translational Oncology 3/2014 Go to the issue

Research Article

Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours

Research Article

Overexpressed transcription factor FOXM1 is a potential diagnostic and adverse prognostic factor in postoperational gastric cancer patients

Educational Series - Red Series

Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy

Research Article

Combined preoperative CEA and CD44v6 improves prognostic value in patients with stage I and stage II colorectal cancer

Research Article

The clinical significance of memory T cells and its subsets in gastric cancer

Research Article

Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits